Syndax Pharmaceuticals, Inc.

NasdaqGS SNDX

Syndax Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Syndax Pharmaceuticals, Inc. Capital Expenditure is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Syndax Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 100.00% change year over year.
Syndax Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -354.00 K, a 0.00% change year over year.
Syndax Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
Syndax Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 100.00% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: SNDX

Syndax Pharmaceuticals, Inc.

CEO	Mr. Michael A. Metzger M.B.A.
IPO Date	March 2, 2016
Location	United States
Headquarters	35 Gatehouse Drive
Employees	184
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Key trends

Past 5 years